| 85.37 -1.1 (-1.27%) | 04-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 111.32 | 1-year : | 130.03 |
| Resists | First : | 95.31 | Second : | 111.32 |
| Pivot price | 88.09  |
|||
| Supports | First : | 80.52 | Second : | 71.38 |
| MAs | MA(5) : | 87.28  |
MA(20) : | 87.07 |
| MA(100) : | 76.15 |
MA(250) : | 56.95 |
|
| MACD | MACD : | 2.7 |
Signal : | 3.6 |
| %K %D | K(14,3) : | 32 |
D(3) : | 40.2 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 95.31 | Low : | 34.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APGE ] has closed above bottom band by 23.0%. Bollinger Bands are 21.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.66 - 89.24 | 89.24 - 89.77 |
| Low: | 82.66 - 83.39 | 83.39 - 84.05 |
| Close: | 85.33 - 86.49 | 86.49 - 87.54 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Tue, 28 Apr 2026
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Tue, 28 Apr 2026
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
Mon, 27 Apr 2026
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters - Yahoo Finance
Sat, 25 Apr 2026
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Fri, 24 Apr 2026
Apogee Therapeutics, Inc. ($APGE) CEO 2025 Pay Revealed - Quiver Quantitative
Fri, 24 Apr 2026
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 127.5 (%) |
| Shares Short | 9,730 (K) |
| Shares Short P.Month | 8,620 (K) |
| EPS | -4.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.2 % |
| Return on Equity (ttm) | -31.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -227 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -20.23 |
| PEG Ratio | 0 |
| Price to Book value | 6.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|